This document provides highlights from the European Society for Medical Oncology (ESMO) Annual Meeting in 2023, specifically focusing on pancreatic, hepatic, and biliary tract cancer. The document discusses various clinical trials and studies related to these types of cancer. For localized pancreatic cancer, the PREOPANC-2 trial compared different treatment approaches and found that gemcitabine-based chemoradiotherapy was more effective than neoadjuvant FOLFIRINOX. In advanced pancreatic cancer, the JCOG1611-GENERATE trial showed that nab-paclitaxel plus gemcitabine was more effective than modified FOLFIRINOX or S-IROX. The document also mentions studies on hepatocellular carcinoma and cholangiocellular cancer, highlighting the use of targeted therapies. Overall, the document provides valuable information for researchers and healthcare professionals interested in these areas of oncology. [Extracted from the article]